Written by
Mustafa Çelik
Mustafa Çelik Liv Hospital Content Team
Medically reviewed by

Related Doctors

Assoc. Prof. MD. Evrim Duman Liv Hospital Ulus Assoc. Prof. MD. Evrim Duman Radiation Oncology Asst. Prof. MD. Meltem Topalgökçeli Selam Liv Hospital Ulus Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology Prof. MD. Duygu Derin Liv Hospital Ulus Prof. MD. Duygu Derin Medical Oncology Prof. MD. Emre Merdan Fayda Liv Hospital Ulus Prof. MD. Emre Merdan Fayda Radiation Oncology Prof. MD. Meral Günaldı Liv Hospital Ulus Prof. MD. Meral Günaldı Medical Oncology Assoc. Prof. MD. Murat Ayhan Liv Hospital Vadistanbul Assoc. Prof. MD. Murat Ayhan Medical Oncology Prof. MD.  Itır Şirinoğlu Demiriz Liv Hospital Vadistanbul Prof. MD. Itır Şirinoğlu Demiriz Hematology Prof. MD. Tülin Tıraje Celkan Liv Hospital Vadistanbul Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology Assoc. Prof. MD. Erkan Kayıkçıoğlu Liv Hospital Bahçeşehir Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology Assoc. Prof. MD. Mine Dağgez Liv Hospital Bahçeşehir Assoc. Prof. MD. Mine Dağgez Gynecological Oncology Assoc. Prof. MD. Ozan Balakan Liv Hospital Bahçeşehir Assoc. Prof. MD. Ozan Balakan Medical Oncology MD. Taylan Bükülmez Liv Hospital Bahçeşehir MD. Taylan Bükülmez Radiation Oncology Op. MD. Alp Koray Kinter Liv Hospital Bahçeşehir Op. MD. Alp Koray Kinter Gynecological Oncology Prof. MD. Nuri Faruk Aykan Liv Hospital Bahçeşehir Prof. MD. Nuri Faruk Aykan Medical Oncology Prof. MD. Yasemin Altuner Torun Liv Hospital Bahçeşehir Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology Spec. MD. Özlem Doğan Liv Hospital Bahçeşehir Spec. MD. Özlem Doğan Medical Oncology Assoc. Prof. MD. Emir Çelik Liv Hospital Topkapı Assoc. Prof. MD. Emir Çelik Medical Oncology Assoc. Prof. MD. Muhammed Mustafa Atcı Liv Hospital Topkapı Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology Prof. MD. İrfan Çiçin Liv Hospital Topkapı Prof. MD. İrfan Çiçin Medical Oncology Assoc. Prof. MD.  Ramazan Öcal Liv Hospital Ankara Assoc. Prof. MD. Ramazan Öcal Hematology Assoc. Prof. MD. Nazlı Topfedaisi Özkan Liv Hospital Ankara Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology Prof. MD. Fikret Arpacı Liv Hospital Ankara Prof. MD. Fikret Arpacı Medical Oncology Prof. MD. Gökhan Erdem Liv Hospital Ankara Prof. MD. Gökhan Erdem Medical Oncology Prof. MD. Meral Beksaç Liv Hospital Ankara Prof. MD. Meral Beksaç Hematology Prof. MD. Oral Nevruz Liv Hospital Ankara Prof. MD. Oral Nevruz Hematology Prof. MD. Saadettin Kılıçkap Liv Hospital Ankara Prof. MD. Saadettin Kılıçkap Medical Oncology Prof. MD. Sadık Muallaoğlu Liv Hospital Ankara Prof. MD. Sadık Muallaoğlu Medical Oncology Spec. MD. Ender Kalacı Liv Hospital Ankara Spec. MD. Ender Kalacı Medical Oncology Assoc. Prof. MD. Fadime Ersoy Dursun Liv Hospital Gaziantep Assoc. Prof. MD. Fadime Ersoy Dursun Hematology Prof. MD. Fatih Teker Liv Hospital Gaziantep Prof. MD. Fatih Teker Medical Oncology Spec. MD. ELXAN MEMMEDOV Liv Bona Dea Hospital Bakü Spec. MD. ELXAN MEMMEDOV Medical Oncology Spec. MD. Ceyda Aslan Spec. MD. Ceyda Aslan Hematology Spec. MD. Elkhan Mammadov Spec. MD. Elkhan Mammadov Medical Oncology Spec. MD. Elmir İsrafilov Spec. MD. Elmir İsrafilov Hematology Spec. MD. Minure Abışova Eliyeva Spec. MD. Minure Abışova Eliyeva Hematology Spec. MD. Natavan Azizova Spec. MD. Natavan Azizova Medical Oncology Prof. MD. Mehmet Hilmi Doğu Liv Hospital Ulus + Liv Hospital Bahçeşehir Prof. MD. Mehmet Hilmi Doğu Hematology
...
Views
Read Time
...
views
Read Time
Acute Lymphoblastic Leukemia in Adults: 7 Key Facts You Must Know
Acute Lymphoblastic Leukemia in Adults: 7 Key Facts You Must Know 2

At Liv Hospital, we understand the importance of being informed about serious health conditions. Acute lymphoblastic leukemia (ALL) is a rare but serious cancer that affects adults. It makes up about 0.3% of all new cancer cases in the U.S. every year.

Understanding this condition is key for patients, families, and doctors. We will share 7 important facts about ALL. These include what it is, who is at risk, its symptoms, how it’s diagnosed, treated, and the chances of survival.

Key Takeaways

  • Understanding ALL is vital for patients and families.
  • ALL is a rare but serious cancer in adults.
  • Early diagnosis and treatment are critical.
  • Survival rates have improved with new treatments.
  • Comprehensive care is essential for managing ALL.

What Is Acute Lymphoblastic Leukemia in Adults?

Bald woman using smartphone during iv therapy
Acute Lymphoblastic Leukemia in Adults: 7 Key Facts You Must Know 3

Exploring Acute Lymphoblastic Leukemia in adults, we find its definition and key differences from childhood ALL. This cancer affects the blood and bone marrow, causing the fast growth of immature white blood cells.

Definition and Basic Pathophysiology

ALL is marked by the uncontrolled growth of lymphoblasts, which are young cells that don’t turn into working lymphocytes. These cells build up in the bone marrow, blocking the creation of normal blood cells.

The disease in ALL comes from many genetic and molecular changes. For example, the Philadelphia chromosome can change the disease’s outlook and treatment. Knowing these changes is key to finding good treatments.

How Adult ALL Differs from Childhood ALL

While ALL is more common in kids, it shows up differently in adults. The main differences are:

  • Biological differences: Adult ALL has unique genetic and molecular traits compared to childhood ALL.
  • Treatment response: Adults usually don’t respond as well to treatment as kids do, because of health issues and different disease types.
  • Prognosis: Adult ALL has a worse outlook than childhood ALL, with lower survival rates over time.

For adults with ALL, knowing these differences is important for understanding their diagnosis and treatment options. For more on leukemia in blood work, check out Liv Hospital’s guide on leukemia diagnosis.

Fact #1: Adult ALL Is Rare But Serious

Midsection of patient resting on bed in hospital
Acute Lymphoblastic Leukemia in Adults: 7 Key Facts You Must Know 4

Adult ALL is a rare cancer in the U.S., but it’s very serious. Looking at the numbers, we see it affects a small number of people. But the impact on those who get it is huge.

Incidence Rate of 0.3% Among All U.S. Cancer Cases

Adult Acute Lymphoblastic Leukemia is rare, making up 0.3% of all new cancer cases in the U.S. Even though it’s rare, we need to know more about it.

Projected Cases and Mortality Rates for 2025

In 2025, about 6,100 new Adult ALL cases are expected, with 1,400 deaths. These numbers show how serious Adult ALL is. They also show why we need to keep working on better treatments.

To get a clearer picture, let’s look at the projected cases and deaths in a table:

YearEstimated New CasesEstimated Deaths
20256,1001,400

Knowing these numbers is key for patients, doctors, and researchers. It shows we need to keep spreading the word, find it early, and find better ways to treat Adult ALL.

Fact #2: Risk Factors for Developing Acute Lymphoblastic Leukemia in Adults

Understanding the risk factors for Adult ALL can lead to early detection and prevention. While we don’t know all causes of Adult ALL, research has found several risk factors.

Genetic Predispositions and Inherited Conditions

Genetics are key in Adult ALL. Certain genetic disorders and inherited conditions raise the risk. For example:

  • Down Syndrome: People with Down syndrome face a higher risk of ALL.
  • Genetic Syndromes: Li-Fraumeni syndrome and ataxia-telangiectasia are linked to a higher ALL risk.
  • Family History: A family history of leukemia or cancer may also raise the risk, more so in childhood ALL.

Environmental Exposures and Lifestyle Factors

Genetics aren’t the only factors. Environmental and lifestyle exposures also play a role in Adult ALL risk.

  • Chemical Exposure: Benzene and pesticides increase leukemia risk.
  • Radiation Exposure: High ionizing radiation, like from nuclear accidents, raises ALL risk.
  • Lifestyle Factors: Smoking and certain diets might influence risk, but more research is needed.

Fact #3: Recognizing the Warning Signs and Symptoms

Spotting the warning signs of adult ALL can greatly improve treatment chances. Adult Acute Lymphoblastic Leukemia often shows symptoms that look like other illnesses. This makes it hard to catch early.

Common Early Symptoms That Shouldn’t Be Ignored

Adults with ALL might feel tired, lose weight, or get sick often. This happens because leukemia cells fill up the bone marrow. This leaves less room for healthy blood cells.

Common symptoms to watch for:

  • Persistent fatigue or weakness
  • Unexplained weight loss
  • Frequent infections
  • Easy bruising or bleeding
  • Pale skin
  • Shortness of breath

When to Seek Medical Attention

If you’re feeling several of these symptoms at once, see a doctor. These signs don’t always mean you have ALL. But, they need a doctor’s check-up to find out why.

Seek immediate medical care if you experience:

  • Severe bleeding or bruising
  • High fever or severe infection
  • Severe fatigue that interferes with daily activities

Gender Differences in Symptom Presentation

Studies show that men and women might show ALL symptoms differently. Women might feel more tired and anemic. Men might show other symptoms more often.

Knowing these differences can help doctors diagnose faster and more accurately. But, remember, ALL can affect anyone differently, no matter their gender.

Fact #4: The Diagnostic Journey for Adult ALL Patients

The journey to diagnose adult ALL is complex. It includes many tests to confirm the disease and its type. Doctors use clinical checks, lab tests, and special procedures to make the diagnosis.

Initial Screening and Blood Tests

The first step is a detailed medical history and physical check-up. Blood tests follow to look for unusual cell counts and shapes. A complete blood count (CBC) is key as it can hint at leukemia through anemia, low platelets, or high white blood cells.

These tests also check the patient’s overall health and spot any issues early. Though not final, they guide the next steps in diagnosis.

Bone Marrow Biopsy and Advanced Diagnostics

A bone marrow biopsy and aspiration are needed for a sure diagnosis of ALL. A sample from the hip bone is taken for a close look. The sample is checked for cancer cells, their traits, and genetic changes.

Tests like flow cytometry, cytogenetic analysis, and molecular testing are used on the sample. They help find the ALL subtype, which is key for treatment and outlook.

Understanding Your ALL Subtype Classification

Diagnosing ALL is not just confirming it’s there. It’s also about knowing its specific traits. ALL types are based on the genetic and molecular makeup of cancer cells.

Knowing the ALL subtype is vital. It affects treatment choices and how well you might do. Some genetic changes might mean higher risk or need for specific treatments.

Diagnostic TestPurposeInformation Provided
Complete Blood Count (CBC)Initial screeningAbnormalities in blood cell counts
Bone Marrow BiopsyDefinitive diagnosisPresence of leukemic cells, cell characteristics
Flow CytometryImmunophenotypingCell surface markers, ALL subtype
Cytogenetic AnalysisGenetic analysisChromosomal abnormalities, prognostic information

Knowing about the diagnostic process helps adult ALL patients understand their treatment better. It empowers them to make informed choices about their care.

Fact #5: Treatment Options for Acute Lymphoblastic Leukemia in Adults

The treatment for adult ALL is changing fast. New treatments are being found as we learn more about the disease.

Standard Chemotherapy Protocols

Chemotherapy is key for treating adult ALL. It uses many drugs in different phases. The goal is to get rid of all leukemia cells.

Key Chemotherapy Agents:

  • Vincristine
  • Anthracyclines (e.g., daunorubicin)
  • Corticosteroids (e.g., prednisone)
  • Asparaginase

Targeted Therapies and Immunotherapies

Targeted and immunotherapies are new hopes for adult ALL. They target specific parts of leukemia cells or use the immune system.

Examples include:

  • TKI therapy for Philadelphia chromosome-positive ALL
  • Monoclonal antibodies (e.g., blinatumomab)
  • CAR-T cell therapy

Stem Cell Transplantation Considerations

Stem cell transplantation can cure adult ALL. It replaces the bone marrow with healthy cells from the patient or a donor.

Transplant TypeDescriptionIndications
AutologousUsing the patient’s own stem cellsFirst remission in high-risk patients
AllogeneicUsing donor stem cellsRelapsed or refractory disease, high-risk features

Emerging Treatment Approaches

New treatments for adult ALL are being researched. These include new targeted therapies, immunotherapies, and combining old treatments.

As research keeps improving, we’ll see better treatments for adult ALL soon.

Fact #6: Survival Rates and Prognosis Factors

It’s important for adult patients with Acute Lymphoblastic Leukemia to know about survival rates and prognosis factors. The outlook for adults with ALL has gotten better over time. This is thanks to new treatments and a better understanding of the disease.

Current 5-Year Survival Rate

The 5-year survival rate for adults with ALL is now about 73%. This shows a big improvement in how well treatments work. It’s thanks to better chemotherapy, targeted therapies, and care to support patients.

Factors Influencing Treatment Outcomes

Several things can affect how well adults with ALL do after treatment. These include:

  • Age: Older adults often face more challenges because of other health issues and less ability to handle strong treatments.
  • Genetic abnormalities: Some genetic changes can make the disease more or less serious.
  • Response to initial treatment: Those who quickly get into complete remission usually do better.
  • Minimal Residual Disease (MRD): If MRD is found after treatment, it means there’s a higher chance of the disease coming back.

Why Adult Outcomes Differ from Pediatric Cases

Adults with ALL have different outcomes than kids for several reasons:

  1. Biological differences: Adult ALL often has different genes and molecules than childhood ALL.
  2. Tolerance to treatment: Adults usually can’t handle as much chemotherapy as kids can.
  3. Comorbidities: Adults are more likely to have other health problems that make treatment harder.

It’s key to understand these differences. This helps create treatments that are right for adults, not just kids.

Fact #7: Long-term Considerations for Adult ALL Survivors

Adult ALL survivors face a new journey after treatment ends. Improving treatment for Acute Lymphoblastic Leukemia is key. We must tackle the long-term challenges survivors encounter.

Managing Late Effects of Treatment

Adult ALL survivors must manage treatment’s late effects. These can include physical and emotional challenges. Cardiac complications are a concern due to some chemotherapy agents. Regular monitoring and follow-up care are vital to reduce these risks.

“Survivors need to be aware of the late effects and work closely with their healthcare team to manage them effectively.”

Follow-up Care and Monitoring

Follow-up care is essential for long-term survival. It includes regular check-ups, monitoring for relapse, and managing side effects. A care plan should be tailored to the individual’s needs, considering their treatments.

“The goal of follow-up care is not just to monitor for recurrence but also to address the physical, emotional, and social needs of survivors.”

Survivors should get guidance on a healthy lifestyle. This includes diet, exercise, and avoiding harmful substances.

Quality of Life After ALL

Improving quality of life is a key part of long-term care. It involves managing medical issues and addressing psychological and social challenges. Support groups and counseling are vital in helping survivors cope and reintegrate into their lives.

By focusing on these long-term considerations, we can improve the well-being of adult ALL survivors. It’s a team effort that requires collaboration between healthcare providers, survivors, and their support networks.

Coping Strategies and Support Resources

Dealing with Acute Lymphoblastic Leukemia (ALL) treatment is not just about medical care. It also requires emotional strength and support. We face emotional, financial, and social challenges during this time.

Emotional and Psychological Support

Adult ALL patients need emotional and psychological support. The diagnosis and treatment can cause anxiety, depression, and stress. Counseling and therapy offer a safe place to share feelings and concerns.

Family and friends play a big role in support. They offer emotional support, help with daily tasks, and go to medical appointments with patients. Support groups, both in-person and online, connect patients with others facing similar challenges. This builds a sense of community and understanding.

Support Groups and Community Connections

Connecting with others who understand ALL challenges is very helpful. Support groups offer a place to share experiences, advice, and emotional support. There are in-person groups and online forums and social media groups.

Community connections go beyond support groups. There are cancer support centers, wellness programs, and survivor networks for more support and connection.

By using these coping strategies and support resources, adult ALL patients can better handle their diagnosis and treatment. This improves their quality of life.

Breakthrough Research Advancing Adult ALL Treatment

The field of Adult ALL treatment is changing fast. New research and clinical trials are leading the way. We’re learning more about this disease and finding new ways to help patients.

Recent Scientific Discoveries

New studies have uncovered important details about Adult ALL. Next-generation sequencing has helped find specific genetic mutations. This knowledge is helping us develop better treatments.

One key finding is about minimal residual disease (MRD). MRD are cancer cells left after treatment. Watching MRD levels helps doctors know how well a treatment is working.

Promising Clinical Trials

Many clinical trials are testing new treatments for Adult ALL. These new methods aim to make treatments more effective and less harsh.

Blinatumomab, a special antibody, is showing great promise. Trials have shown it can improve survival rates and reduce side effects compared to old treatments.

How to Access Cutting-Edge Treatments

To get these new treatments, patients need a healthcare team involved in research. Specialized treatment centers often join the latest trials. This gives patients a chance to try new therapies.

Patients can find trials on ClinicalTrials.gov. It’s important to talk to a doctor about the benefits and risks of joining a trial. This helps decide the best treatment plan.

As research keeps moving forward, the future for Adults with ALL looks brighter. By keeping up with new findings and working with doctors, patients can get the best treatments available.

Specialized Treatment Centers for Adult ALL

Specialized treatment centers are key in managing adult Acute Lymphoblastic Leukemia (ALL). They have the latest technology and teams of experts. These teams have a lot of experience with this complex disease.. 

Liv Hospital’s Approach to Adult Leukemia Treatment

Liv Hospital offers comprehensive care for adult leukemia patients. They have a team of hematologists, oncologists, and specialists. This team works together to create personalized treatment plans.

Liv Hospital aims to provide top-notch healthcare for international patients. They ensure patients get the best care in a supportive environment.

“The key to successful treatment lies in the ability to offer personalized care that addresses the unique needs of each patient.” – A Dr in Liv Hospital

Questions to Ask Your Healthcare Team

It’s important to ask the right questions to your healthcare team. This ensures you’re getting the best care. Here are some key questions:

  • What are the available treatment options for my specific condition?
  • What are the possible side effects of the treatments?
  • Are there any clinical trials or new treatments I might be eligible for?
  • How will my treatment plan be monitored and adjusted over time?

By asking these questions and choosing a specialized center like Liv Hospital, adult ALL patients get the best care. They receive support throughout their treatment.

Conclusion: Navigating Life After an Adult ALL Diagnosis

Getting a diagnosis of Acute Lymphoblastic Leukemia (ALL) as an adult is tough. It’s important to know about the disease, treatment options, and what to expect. We’ve looked at seven key facts about adult ALL, covering everything from its occurrence to long-term effects.

Getting diagnosed early and getting good care are key to beating ALL. Knowing the signs and acting fast can help a lot. Thanks to new research and treatments, many people are living longer and better lives.

After being diagnosed with ALL, you need ongoing support and care. It’s important to manage treatment side effects, keep up with follow-up care, and get help with emotional and financial issues.

Understanding adult ALL and using available resources can help you manage your diagnosis better. With ongoing research, there’s hope for even better treatments and outcomes in the future.

What is acute lymphoblastic leukemia in adults?

Acute lymphoblastic leukemia (ALL) in adults is a rare and serious cancer. It affects the blood and bone marrow. It’s caused by the fast growth of immature white blood cells.

How does adult ALL differ from childhood ALL?

Adult ALL is different from childhood ALL in many ways. Adults often have more complex genetic mutations. They also have more health problems, making treatment harder.

What are the risk factors for developing adult ALL?

Risk factors for adult ALL include genetic predispositions and inherited conditions. Environmental exposures like radiation and certain chemicals also play a role.

What are the common symptoms of adult ALL?

Symptoms of adult ALL include fatigue, weight loss, and fever. Night sweats and bleeding or bruising easily are also common. Recognizing these symptoms early is key for treatment.

How is adult ALL diagnosed?

Diagnosing adult ALL involves blood tests, bone marrow biopsy, and advanced diagnostics. These include genetic testing and flow cytometry.

What are the treatment options for adult ALL?

Treatments for adult ALL include standard chemotherapy and targeted therapies. Immunotherapies and stem cell transplantation are also options. New treatments are being explored too.

What is the current 5-year survival rate for adult ALL?

The 5-year survival rate for adult ALL is about 73%. This rate can change based on age, genetic mutations, and treatment response.

How can adult ALL survivors manage late effects of treatment?

Survivors can manage late effects by following up regularly and monitoring for complications. Adopting a healthy lifestyle is also important.

What support resources are available for adult ALL patients?

Support for adult ALL patients includes emotional support, financial help, and community connections. There are also support groups available.

How can patients access cutting-edge treatments for adult ALL?

Patients can get new treatments by joining clinical trials. They can also seek care at specialized centers. Staying updated on research is key.

Why is it important to seek care at specialized treatment centers for adult ALL?

Specialized centers offer the latest treatments and technologies. They have experienced teams, improving patient outcomes.

Can adults develop leukemia?

Yes, adults can get leukemia, including ALL. It’s important to get diagnosed and treated quickly.

What is the incidence rate of adult ALL?

Adult ALL is rare, making up about 0.3% of U.S. cancer cases.

Reference

National Cancer Institute (NCI) SEER. Cancer Stat Facts: Acute Lymphoid Leukemia (ALL). https://seer.cancer.gov/statfacts/html/alyl.html

American Journal of Hematology. Research Article. https://onlinelibrary.wiley.com/doi/10.1002/ajh.27708

Blood Cancer United. Acute Lymphoblastic Leukemia (ALL) Research and Development Progress. https://bloodcancerunited.org/research/blood-cancer-research-development-progress/leukemia/acute-lymphoblastic-leukemia-all

i

Medical Disclaimer

The content on this page is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Always consult a qualified healthcare provider regarding any medical conditions.

Book a Free Certified Online
Doctor Consultation

Clinics/branches
GDPR

We're Here to Help.
Get in Touch

Send us all your questions or requests, and our
expert team will assist you.

Our Doctors

Assoc. Prof. MD. Evrim Duman Radiation Oncology

Assoc. Prof. MD. Evrim Duman

Liv Hospital Ulus
Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology

Asst. Prof. MD. Meltem Topalgökçeli Selam

Liv Hospital Ulus
Prof. MD. Duygu Derin Medical Oncology

Prof. MD. Duygu Derin

Liv Hospital Ulus
Prof. MD. Emre Merdan Fayda Radiation Oncology

Prof. MD. Emre Merdan Fayda

Liv Hospital Ulus
Prof. MD. Mehmet Hilmi Doğu Hematology

Prof. MD. Mehmet Hilmi Doğu

Liv Hospital Ulus
Liv Hospital Bahçeşehir
Prof. MD. Meral Günaldı Medical Oncology

Prof. MD. Meral Günaldı

Liv Hospital Ulus
Assoc. Prof. MD. Murat Ayhan Medical Oncology

Assoc. Prof. MD. Murat Ayhan

Liv Hospital Vadistanbul
Prof. MD.  Itır Şirinoğlu Demiriz Hematology

Prof. MD. Itır Şirinoğlu Demiriz

Liv Hospital Vadistanbul
Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology

Prof. MD. Tülin Tıraje Celkan

Liv Hospital Vadistanbul
Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology

Assoc. Prof. MD. Erkan Kayıkçıoğlu

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Mine Dağgez Gynecological Oncology

Assoc. Prof. MD. Mine Dağgez

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Ozan Balakan Medical Oncology

Assoc. Prof. MD. Ozan Balakan

Liv Hospital Bahçeşehir
MD. Taylan Bükülmez Radiation Oncology

MD. Taylan Bükülmez

Liv Hospital Bahçeşehir
Op. MD. Alp Koray Kinter Gynecological Oncology

Op. MD. Alp Koray Kinter

Liv Hospital Bahçeşehir
Prof. MD. Nuri Faruk Aykan Medical Oncology

Prof. MD. Nuri Faruk Aykan

Liv Hospital Bahçeşehir
Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology

Prof. MD. Yasemin Altuner Torun

Liv Hospital Bahçeşehir
Spec. MD. Özlem Doğan Medical Oncology

Spec. MD. Özlem Doğan

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Emir Çelik Medical Oncology

Assoc. Prof. MD. Emir Çelik

Liv Hospital Topkapı
Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology

Assoc. Prof. MD. Muhammed Mustafa Atcı

Liv Hospital Topkapı
Prof. MD. İrfan Çiçin Medical Oncology

Prof. MD. İrfan Çiçin

Liv Hospital Topkapı
Assoc. Prof. MD.  Ramazan Öcal Hematology

Assoc. Prof. MD. Ramazan Öcal

Liv Hospital Ankara
Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology

Assoc. Prof. MD. Nazlı Topfedaisi Özkan

Liv Hospital Ankara
Prof. MD. Fikret Arpacı Medical Oncology

Prof. MD. Fikret Arpacı

Liv Hospital Ankara
Prof. MD. Gökhan Erdem Medical Oncology

Prof. MD. Gökhan Erdem

Liv Hospital Ankara
Prof. MD. Meral Beksaç Hematology

Prof. MD. Meral Beksaç

Liv Hospital Ankara
Prof. MD. Oral Nevruz Hematology

Prof. MD. Oral Nevruz

Liv Hospital Ankara
Prof. MD. Saadettin Kılıçkap Medical Oncology

Prof. MD. Saadettin Kılıçkap

Liv Hospital Ankara
Prof. MD. Sadık Muallaoğlu Medical Oncology

Prof. MD. Sadık Muallaoğlu

Liv Hospital Ankara
Spec. MD. Ender Kalacı Medical Oncology

Spec. MD. Ender Kalacı

Liv Hospital Ankara
Assoc. Prof. MD. Fadime Ersoy Dursun Hematology

Assoc. Prof. MD. Fadime Ersoy Dursun

Liv Hospital Gaziantep
Prof. MD. Fatih Teker Medical Oncology

Prof. MD. Fatih Teker

Liv Hospital Gaziantep
Spec. MD. ELXAN MEMMEDOV Medical Oncology

Spec. MD. ELXAN MEMMEDOV

Liv Bona Dea Hospital Bakü
Spec. MD. Ceyda Aslan Hematology

Spec. MD. Ceyda Aslan

Spec. MD. Elkhan Mammadov Medical Oncology

Spec. MD. Elkhan Mammadov

Spec. MD. Elmir İsrafilov Hematology

Spec. MD. Elmir İsrafilov

Spec. MD. Minure Abışova Eliyeva Hematology

Spec. MD. Minure Abışova Eliyeva

Spec. MD. Natavan Azizova Medical Oncology

Spec. MD. Natavan Azizova

Need Help? Chat with our medical team

Let's Talk on WhatsApp

📌

Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.

or call us at +90 530 510 67 91